VIP Peptide Protects the Gut from Radiation Damage by Boosting Intestinal Stem Cell Regeneration

Vasoactive intestinal peptide (VIP) protects the gut from radiation damage by promoting intestinal stem cell differentiation and regeneration. VIP drove intestinal epithelial cells toward a secretory phenotype primarily through the p38 MAPK signaling pathway and modulated the proliferation of Lgr5+ progenitor cells (intestinal stem cells). After radiation injury, these stem cells became more responsive to VIP's effects, and VIP strongly promoted epithelial regeneration. Critically, these findings held in live mice — VIP injections significantly reduced radiation-induced intestinal damage after abdominal irradiation with 12 Gy.

Researchers grew intestinal organoids (miniature gut structures) from mouse jejunal tissue and treated them with VIP before and after 6 Gy irradiation. They used Lgr5-reporter mice to track intestinal stem cells and their proliferation. For in vivo validation, mice received 12 Gy abdominal irradiation followed by intraperitoneal VIP injections. Analysis included epithelial differentiation markers, stem cell number and activity, and tissue damage assessment.

Radiation damage to the gut is a serious side effect of cancer treatment, with limited options for protection or repair. This study shows that VIP — a natural peptide already present in the gut's nervous system — can protect intestinal stem cells and accelerate gut repair after radiation. This could lead to new supportive treatments for cancer patients undergoing abdominal radiation therapy.

Radiation enteritis — gut damage from cancer radiation — affects thousands of patients and has few effective treatments. This study reveals that the gut's own nervous system produces a peptide (VIP) that can drive intestinal repair. This connects to the growing understanding that the enteric nervous system actively controls gut regeneration, and suggests that neuropeptide-based therapies could become a new approach to protecting the gut during cancer treatment.

This is an animal study using mice — results need to be validated in humans. The organoid model, while informative, does not fully replicate the complexity of the intact human gut environment including immune cells, blood supply, and the microbiome. The radiation doses and VIP administration protocols would need optimization for clinical translation. Long-term effects of VIP treatment on gut tissue were not assessed.